Low expression of therapeutic genes products is a problem that has plagued all approaches in human gene therapy. Much of the effort to overcome this problem has focused on increasing transduction efficiency, promoter activity and altering gene structure to enhance expression. An alternative approach is to increase the net """"""""activity"""""""" of gene products by increasing their transport through the producing tissue, decreasing their clearance from the circulation, or enhancing their stability and targeting to the site of action. To accomplish this, an understanding of fundamental protein transport mechanisms through tissues is required. We have defined several key molecular parameters that theoretically control transport of proteins through tissues and have identified endosomal dissociation and ligand recycling as particularly important. To critically test their importance, epidermal growth factor (EGF) will be systematically modified by site-directed mutagenesis to increase its dissociation from receptors at endosomal pH values. Chimeras between EGF and recycling proteins, such as transferrin, will also be made. The relative trafficking of modified EGF in cultured cells will be determined and compared to their transport through artificial tissues consisting of cells embedded in different matrices. These data will be used to refine a quantitative model of tissue transport. In addition, transport of modified ligands from cell grown to either a nylon matrix or hollow fibers will be followed. The ligand release rates from these devices in vitro will be compared to circulating protein levels following their implantation in athymic mice. This should indicate how context affects transport or different gene products. Finally the studies will be extended to a second type of ligand, keratinocyte growth factor, to determine the extend to which our concepts can be applied to other bioactive molecules. This project should provide basic information on effective strategies to increase activities of therapeutic gene products.

Project Start
2000-12-01
Project End
2001-11-30
Budget Start
Budget End
Support Year
8
Fiscal Year
2001
Total Cost
$204,124
Indirect Cost
Name
University of Utah
Department
Type
DUNS #
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Davis, Howard E; Rosinski, Matthew; Morgan, Jeffrey R et al. (2004) Charged polymers modulate retrovirus transduction via membrane charge neutralization and virus aggregation. Biophys J 86:1234-42
Erdag, Gulsun; Medalie, Daniel A; Rakhorst, Hinne et al. (2004) FGF-7 expression enhances the performance of bioengineered skin. Mol Ther 10:76-85
Erdag, Gulsun; Morgan, Jeffrey R (2004) Allogeneic versus xenogeneic immune reaction to bioengineered skin grafts. Cell Transplant 13:701-12
Woodley, David T; Krueger, Gerald G; Jorgensen, Cynthia M et al. (2003) Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J Invest Dermatol 121:1021-8
Erdag, Gulsun; Morgan, Jeffrey R (2002) Interleukin-1alpha and interleukin-6 enhance the antibacterial properties of cultured composite keratinocyte grafts. Ann Surg 235:113-24
Hamoen, Karen E; Morgan, Jeffrey R (2002) Transient hyperproliferation of a transgenic human epidermis expressing hepatocyte growth factor. Cell Transplant 11:385-95
Davis, Howard E; Morgan, Jeffrey R; Yarmush, Martin L (2002) Polybrene increases retrovirus gene transfer efficiency by enhancing receptor-independent virus adsorption on target cell membranes. Biophys Chem 97:159-72
DeWitt, Ann; Iida, Tomoko; Lam, Ho-Yan et al. (2002) Affinity regulates spatial range of EGF receptor autocrine ligand binding. Dev Biol 250:305-16
Gill, Pritmohinder S; Krueger, Gerald G; Kohan, Donald E (2002) Doxycycline-inducible retroviral expression of green fluorescent protein in immortalized human keratinocytes. Exp Dermatol 11:266-74
Erdag, Gulsun; Morgan, Jeffrey R (2002) Survival of fetal skin grafts is prolonged on the human peripheral blood lymphocyte reconstituted-severe combined immunodeficient mouse/skin allograft model. Transplantation 73:519-28

Showing the most recent 10 out of 42 publications